Acorah Software Products - Accounts Production 19.4.351 false true false true No description of principal activity 14 January 2025 31 January 2026 31 January 2026 16183444 Dr C Graham Miss E Graham iso4217:GBP iso4217:EUR iso4217:USD xbrli:shares xbrli:pure xbrli:pure 16183444 2025-01-13 16183444 2026-01-31 16183444 2025-01-14 2026-01-31 16183444 frs-core:CurrentFinancialInstruments 2026-01-31 16183444 frs-bus:PrivateLimitedCompanyLtd 2025-01-14 2026-01-31 16183444 frs-bus:FilletedAccounts 2025-01-14 2026-01-31 16183444 frs-bus:Micro-entities 2025-01-14 2026-01-31 16183444 frs-bus:AuditExempt-NoAccountantsReport 2025-01-14 2026-01-31 16183444 frs-bus:Director1 2025-01-14 2026-01-31 16183444 frs-bus:Director2 2025-01-14 2026-01-31
Registered number: 16183444
CTG Pathology Limited
Financial Statements
For the Period 14 January 2025 to 31 January 2026
Balance Sheet
Registered number: 16183444
31 January 2026
£
Current assets 17,432
Prepayments and accrued income 3,098
Creditors: Amounts Falling Due Within One Year (4,958 )
NET CURRENT ASSETS 15,572
TOTAL ASSETS LESS CURRENT LIABILITIES 15,572
Accruals and deferred income (700 )
NET ASSETS 14,872
CAPITAL AND RESERVES 14,872

Notes

1. General Information
CTG Pathology Limited is a private company, limited by shares, incorporated in England & Wales, registered number 16183444 . The registered office is 3 Walnut Drive, Wendover, Aylesbury, Buckinghamshire, HP22 6RT.
2. Average Number of Employees
Average number of employees, including directors, during the period was: 1
1
Page 0
Page 1
For the period ending 31 January 2026 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared in accordance with the micro-entity provisions and delivered in accordance with the provisions applicable to companies subject to the small companies regime.
On behalf of the board
Dr C Graham
Director
7 October 2026